PEDIATRICS Vol. 31 No. 5 May 1963, pp. 833-839
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perrin, J. C. S.
Right arrow Articles by Sterling, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perrin, J. C. S.
Right arrow Articles by Sterling, T. D.

INTRAVENOUS METHOTREXATE (AMETHOPTERIN) THERAPY IN THE TREATMENT OF ACUTE LEUKEMIA

Jane C. S. Perrin M.D.1, Alvin M. Mauer M.D.1, and Theodor D. Sterling Ph.D.1

1 The Departments of Pediatrics and Biometrics, The University of Cincinnati College of Medicine, and The Children's Hospital Research Foundation, Cincinnati, Ohio

Fourteen children with acute leukemia were treated with bi-weekly intravenous injections of methotrexate (amethopterin) after relapse during oral chemotherapy. Twelve of these children obtained a remission from the therapy with an average duration of 4.4 months for the 14 patients. The median survival time was 19.5 months for the group, with six patients still living. A statistical method based on regression analysis was used to determine the significance of the difference in the results obtained in the study group and in a control group of 36 patients treated at this hospital between 1955 and 1959. It was concluded that intravenous methotrexate therapy prolonged the survival of these patients and was a useful therapeutic adjunct.

Submitted on July 25, 1962
Accepted on November 23, 1962